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A B S T R A C T
Tuberculosis still remains a global health emergency, claiming 1.5 million lives in 2013. The bacterium
responsible for this disease, Mycobacterium tuberculosis (M.tb), has successfully survived within hostile
host environments, adapting to immune defence mechanisms, for centuries. This has resulted in a
disease that is challenging to treat, requiring lengthy chemotherapy with multi-drug regimens. One
explanation for this difﬁculty in eliminating M.tb bacilli in vivo is the disparate action of antimicrobials
on heterogeneous populations of M.tb, where mycobacterial physiological state may inﬂuence drug
efﬁcacy. In order to develop improved drug combinations that effectively target diverse mycobacterial
phenotypes, it is important to understand how such subpopulations of M.tb are formed during human
infection. We review here the in vitro and in vivo systems used to model M.tb subpopulations that may
persist during drug therapy, and offer aspirations for future research in this ﬁeld.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-
nc-sa/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Pathogenesis of Mycobacterium tuberculosis – an overview
Tuberculosis, a disease caused by Mycobacterium tuberculosis,
is primarily transmitted through the respiratory route. Individu-
als become infected when they inhale aerolised particles
produced by patients with active disease. These droplet nuclei
(measuring 1-3 mm and containing 1-3 bacilli) are then engulfed
by alveolar macrophages, where M. tuberculosis (M.tb) bacilli are
able to evade killing and continue to multiply by avoiding
phagosome-lysosome fusion.1 Additional macrophages and other
immune cells then become localised to the site of infection
creating an ordered cellular architecture known as a granuloma.
These dynamic structures evolve from simple cellular aggrega-
tions with vascular elements to necrotic lesions characterised by
hypoxia and nutrient deprivation.2,3 Caseous necrosis often
ensues; this consists of the ‘‘solid’’ necrosis of the exudative
lesion and some of the lung tissue that surrounds it. The process
likely results in the death of the majority of M.tb bacilli but some
will survive extracellularly in the solid caseous material. Caseous
necrosis can result in the abolishment of the neighbouring host
tissues and if this destruction reaches the bronchiolar barrier then* Corresponding author. Tel.: +02077940500x31146. Email address: d.evange-
lopoulos@ucl.ac.uk. Corresponding Editor: Eskild Petersen.
E-mail address: d.evangelopoulos@ucl.ac.uk (D. Evangelopoulos).
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license (http://creativecommons.org/licenses/by-nc-sa/4.0/).a cavity is formed, creating a route of dissemination for M.tb bacilli
through the airways.4 The M.tb load in tuberculous cavities may
reach 1011 CFUs (Colony Forming Units) per gram, with bacilli
presumably replicating rapidly in this environment.5 Thus
patients with cavitation are highly infectious.6 Furthermore,
the degree of cavitation is often one of the only factors associated
with treatment failure.7 Thus, M.tb bacilli are able to survive in
multiple diverse and dynamic environments during infection;
drug regimens that are able to kill bacilli in all these niches are
likely to offer the best opportunity to reduce treatment length and
eliminate relapse.
2. M. tuberculosis populations within the host
The pathogenesis of M. tuberculosis creates bacterial phenotypic
heterogeneity, deﬁned here as a mixture of genetically identical
bacteria that vary in measured characteristic(s). This heterogeneity
may impact upon the metabolic state of M.tb and/or the efﬁcacy of
antimicrobials. Thus M.tb infection rather resembles, and might be
approached as, a polymicrobial infection where several cidal
activities are required for M.tb sterilisation by chemotherapy.
When exposed to bactericidal concentrations of antimicrobial
drugs, the number of viable cells in a susceptible bacterial
population does not decline exponentially. Instead, the mortality
rate decreases over time and a substantial fraction of the
population may survive antimicrobial drug treatment. Thisciety for Infectious Diseases. This is an open access article under the CC BY-NC-SA
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used in clinical practice and for many bacterial species8–14 and has
been attributed to antimicrobial tolerance. Phenotypic antimicro-
bial tolerance is a temporary, reversible bacterial state that is often
associated with a reduced rate of multiplication, where some
antimicrobial drugs are ineffective against genetically susceptible
bacilli. Antimicrobial tolerance is hypothesised to be the prime
reason for the extended treatment regimens required for M.tb
chemotherapy, as fully drug-sensitive bacilli survive (persist
through) initial antimicrobial drug therapy.15–17 It has long been
speculated that M.tb in a non/slowly-replicating state may play a
clinically signiﬁcant role, persisting during drug therapy.18–20 The
ﬁrst-line antimicrobials used to treat M.tb infection (isoniazid,
rifampicin, pyrazinamide and ethambutol) are all active against
actively-replicating bacteria,21 however effectiveness of this drug
regimen against non/slowly-replicating bacilli is reduced or
eliminated.22–24 This M.tb slow/non-replicating state is hypothe-
sised to be induced by the environmental conditions found in
speciﬁc granuloma types, in particular those associated with
hypoxia or nitric oxide production.18,25,26 An M.tb transcriptional
signature resembling slow or non-replicating bacilli was also
identiﬁed in bacilli isolated from human sputa.27 Exposure of
bacilli to such microenvironments results in the expression of a
discrete set of genes known as the dormancy regulon (DosR/DevR)
that are in turn responsible for transitioning bacilli into a non-
replicating and hence likely drug-tolerant state.25,28-30 The
mechanism(s) that result in the generation of phenotypic drug
tolerant M.tb populations in vivo are currently not well understood,
however it is critical to consider these sub-populations of bacilli for
the development of more effective drug regimes.
The M.tb population in vivo has been compared to a Russian
nesting doll, consisting of layer after layer of distinct bacterial
subpopulations that may also be separated by time and space, each
of which may be differentially killed by various antimicrobial
drugs dependent on phenotypic drug tolerance or anatomical
location. The models developed by Mitchison31 and Mitchison and
Coates17,32 are often adapted to describe four populations deﬁned
by antimicrobial drug efﬁcacy (1) actively growing bacilli mostly
killed by isoniazid, (2) slow/non-replicating M.tb bacteria that
undergo spurts of metabolism, which are killed by rifampicin, (3)
intracellular bacilli present in the acidic compartments of
macrophages or in acidic lung lesions that are killed by
pyrazinamide, and (4) M.tb persisters found in hypoxic micro-
environments with much reduced action of most anti-TB
drugs.22,33 As evidenced in TB patients that relapse during
treatment of drug-sensitive M.tb, the host immune system cannot
effectively eliminate these residual M.tb bacilli that are not killed
by chemotherapy. Therefore, although achieving a clinical cure, the
current anti-TB standard regimen does not necessarily achieve a
bacteriological cure. In other words, current therapy does not
completely eradicate all bacilli from the body, but allows the
infection to be contained effectively for long-periods of time.34
These observations underscore the need for developing better
sterilising compounds against M.tb. However, the lack of adequate
screening systems able to identify new compounds effective
against drug-tolerant M.tb phenotypes remains an immense
barrier to the anti-tuberculosis drug development process.35
3. Models to study M. tuberculosis populations that may persist
during drug therapy
3.1. In vitro studies
Several models have been developed to recreate conditions
encountered by M.tb within the host during infection. Since
the nomenclature surrounding M.tb dormancy and latency isambiguous, we refer to these models here simply as systems that
generate populations of bacilli that may persist (or at least be
differentially killed) by antimicrobials during disease. The in vitro
systems necessarily only capture speciﬁc aspects of the clinical
scenario. These models mimic stimuli hypothesised to be present
during infection and may be divided into two groups: (1) Those
designed to generate a largely homogenous bacterial population to
characterise speciﬁc responses and develop drug screens for
deﬁned bacterial phenotypic states. (2) Those aimed at producing
mixed populations of M.tb, often with multiple stimuli to model
drug action on heterogeneous populations. Of course, bacterial
heterogeneity is entirely deﬁned by the methods used to
characterise M.tb populations and the resolution of the techniques.
The method described by Wayne and colleagues is the most
frequently used experimental approach to hypoxia and, hence, the
best characterised. In this model, M.tb is grown under agitation in
air-tight containers with a deﬁned headspace-to-culture ratio and
for a deﬁned period of time (usually 24 days), which leads to the
gradual depletion of oxygen.23 When deprived of oxygen, the
bacilli enter a non-replicative state that is refractory to isoniazid-
dependent killing.36 This physiological state may be reversed by
exposure to atmospheric oxygen conditions.22,37 The Wayne
model has been used for the evaluation of new compounds;
non-replicating phase 2 (NRP2) bacilli were treated with test drugs
and subsequent mycobacterial growth was determined by
conventional plating methods.38 Using similar methodology,
metronidazole and PA-824 (a nitroimidazo-oxazine now in phase
2 and 3 clinical trials) were shown to be active against anaerobic
M.tb in vitro.38 Several versions of the Wayne model have been
developed to increase its throughput capacity, for example, by
combining with colorimetric or luminescence-based measures of
bacterial viability.35,39,40 In addition, using multiple genome-wide
analyses, Galagan and colleagues have been able to explore the
molecular mechanisms that are employed by M.tb during hypoxia
and reaeration phases.41
Deprivation of nutrients is another stress hypothesised to be
encountered by M.tb inside granulomas. The models that repro-
duce this condition normally involve the incubation of tubercle
bacilli in minimal medium for approximately 6 weeks. During this
period, the cells undergo a global metabolic shift:42,43 several
metabolic pathways are shut down and lipids become the sole
source of energy;44 while rescue pathways, such as those involved
in the synthesis of vital enzymes, are upregulated. Aerobic
respiration usually shuts down after 9-12 days. Starvation-
induced persistent-bacilli are tolerant to some antimicrobials, such
as isoniazid, rifampicin and metronidazole. However, pyrazina-
mide, econazole and clotrimazole are active against this M.tb
population.42,45,46 Chemostat models are a key resource for such
investigations where a controlled environment is achieved by ﬁne-
tuning bacterial growth rate alongside parameters affecting the
respiratory and metabolic state of bacilli. Chemostats have been
successfully used to study the molecular adaptations of myco-
bacteria to nutrient depletion,47 low oxygen tension,48 and
between fast-growing and slow-growing populations.49 Additional
single stress models have been developed by either limiting the
availability of speciﬁc nutrients or inducing a stress predicted to be
present in vivo, for example low potassium,50 PBS starvation
model,42 reduced oxygen, low pH.51,52
Hypoxia and nutrient starvation models can trigger M.tb to slow
growth and activate the DosR/DevR regulon, however they cannot
simulate the multiple environmental stimuli that are likely found
within granulomas, as bacilli adapt to the dynamic surroundings.
For this reason, multiple-stress models (combining hypoxia,
nutrient starvation, low pH) may offer a more complete in vitro
simulation of the circumstances bacilli encounter in some human
lung lesions.53 The model developed by Deb et al. was shown to
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characteristics of bacilli that may persist during drug therapy.
This model has not been used widely for drug screening but might
represent a good alternative. In addition, in vitro bioﬁlm models
have been developed to model the generation of complex
mycobacterial populations, and antimicrobial drug-tolerant states,
which may be utilised toward exploring the action of novel drugs
against heterogeneous M.tb populations.54 Furthermore, nano-
technology systems such as microﬂuidic devices offer revolution-
ary novel approaches to studying bacterial subpopulations and the
development of persisting organisms by monitoring the fate of
single bacterial cells within a population.55,56
All the above in vitro models have the obvious limitation of not
being able to reproduce the effects of the host: immune response,
cellular architecture, macrophage phagocytosis and eventual
release to the extracellular milieu. Macrophage infection models
are available that mimic the early M.tb responses to the host
immune system but fail to capture long-term metabolic
changes.25,57-59 The transcriptional adaptations of M.tb to the
intracellular environment have also been deﬁned using mRNA
proﬁling to identify key metabolic and respiratory changes, and to
identify factors that drive the generation of M.tb phenotypes
during infection.60-63 Intracellular models of drug action reveal
that antimicrobials differ in their abilities to kill intracellular
bacteria, likely a combination of drug penetration and efﬁcacy
against intracellular-adapted M.tb phenotypes that may be in part
drug-tolerant.58 Techniques such as high content screening have
been developed to model intracellular drug efﬁcacy, alongside
drug penetration and toxicity.59
Another possibility is the development of in vitro human
granuloma models.64 The availability of a granuloma model could
provide a useful strategy for the study of drug efﬁcacy against
drug-tolerant M.tb. Several groups have attempted to develop such
a model,65-67 but, thus far, only one has generated M.tb cells with
the characteristics of persistent mycobacteria.68
3.2. Pre-clinical animal models
There are several animal models available for the study of
persistent TB infection and the determination of the in vivo
activity of novel compounds; these include mouse, guinea pig,
rabbit, non-human primate and zebraﬁsh models.69 Animal
models not only offer the possibility of circumventing the
limitations discussed above (by including host in the modelling)
but also allow an early assessment of the drug’s toxicity to the
host, and the ability to test a compound’s activity against cell
processes that only manifest in vivo during host/pathogen
interaction.70 However, the difﬁculties in developing and
manipulating animal models of TB infection, and the assessment
of the clinical relevance of each system, means that animal models
are also not without limitations.
There are two established murine models for the study of latent
TB, which generate populations of M.tb that persist through drug
treatment. (1) In the Cornell model69mice are inoculated with high
dose (1x106-3x106 CFU) M.tb bacilli and subsequently treated with
isoniazid and pyrazinamide for 12 weeks. By the end of this
treatment, the mice do not show obvious signs of disease and the
bacterial loads in organ homogenates are reduced to undetectable
levels, suggested to mimic latent human infection. The presence of
M.tb populations that persist through drug therapy is shown by
spontaneous (in about one third of animals by week 3 after
treatment) or steroid-induced (in almost all mice) relapse. The
bacilli recovered from these murine relapse cases are acid fast and
fully susceptible to isoniazid and pyrazinamide administered
before. Several modiﬁed versions of this model optimising
parameters such as duration of drug therapy and drug dosageshave been proposed.71,72 (2) In the second model, mice are
inoculated via the respiratory route with a low dose of M.
tuberculosis (5-10 CFU).73 This low dose model relies solely on the
natural host immune response to control the infection; approxi-
mately 3 months after inoculation the pulmonary bacterial load
stabilises at around 3 to 4 log10.73 This clinically quiescent phase
of the infection may be maintained for up to 1.5 years, after which
the mice begin to relapse. To determine the activity of new
compounds against M.tb in these models, test drugs are adminis-
tered to mice in the latent phase of infection, followed by
immunosuppressive treatment to allow the reactivation of bacilli
and enumeration of viable cells in tissue homogenates.74 Using this
approach, metronidazole was found to be unable to prevent
reactivation of TB infection in mice, while the azole antifungal
econazole was shown to signiﬁcantly reduce the bacterial burden
in lungs and spleens of these infected mice.46,75 However, the
disparate TB pathologies between murine and human lungs, mice
do not develop organised granulomas with caesous necrosis or
mineralisation,45,76 mean that these observations may not be
reproduced in human studies.
The gross pathology of tuberculosis disease in guinea pigs
and rabbits more closely resembles that of humans, with similar
mechanisms of granuloma formation and associated case-
ation.77-80. Furthermore, rabbit granulomas may progress to
liquefaction and cavitation.81,82 The rabbit model of latent
TB83,84 is characterised by persistent, host-contained pauciba-
cillary infection that may be reactivated by immunosuppressive
treatment. This makes it an attractive model to study drug
efﬁcacy against persistent M.tb.2 In addition, the existence of
non-replicating tubercle bacilli in lung lesions of guinea pigs,
sharing similarities with those found in humans, has been
conﬁrmed.79 The similarities between M.tb natural infection in
humans and guinea pigs also provide evidence to suggest that
non-human primate models are probably the most relevant for
studying drug-persistent TB as they capture the spectrum of
human tuberculous lung pathology.25,69 However, these are also
the most costly and resource-intensive models.2 This, together
with concerns over the reproducibility of these models
(associated with genotype variability and small sample sizes)
and adverse public opinion, limit the widespread use of non-
human primate models for TB drug discovery programmes.69,85
4. Need for better models to evaluate the efﬁcacy of drugs against
speciﬁc M.tb subpopulations
Human infection with M.tb is a complex and multi-factorial
process involving the immuno-modulation and remodelling of
multiple tissues over many years. Within granulomas, for example,
there is a gradient of active, inactive and dead immune cells and
bacteria, changing oxygen potential and nutrient composition.
These diverse scenarios result in a complex M.tb population
structure, composed of bacilli in different metabolic states that are
killed at different rates by the spectrum of antimicrobial drugs.
The requirement for lengthy TB chemotherapy likely reﬂects
the inability of current antimicrobial drugs to eradicate sub-
populations of M.tb bacilli, enabling these populations of bacteria
to persist in infected individuals. It is therefore crucial to develop
new drugs that can effectively eliminate these persisting cells. A
sequence of in vitro assays and animal models of M.tb mimicking
TB infection are applied in drug discovery and development to
identify and select active compounds. Unfortunately, the tools
currently available have a limited ability to predict the activity of
new drugs against M.tb bacilli that are able to survive in human
disease during chemotherapy. It is therefore critical to develop
practical, robust, and high-throughput models that can accurately
reproduce M.tb subpopulations found in vivo; this will enable novel
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sterilisation more effectively, reducing treatment length.
Persistence through drug therapy in M.tb has been associated
with a non-replicative state resistant to standard anti-TB drugs
(such as isoniazid and rifampicin), loss of acid-fastness, RPF-
dependency and accumulation of lipid bodies. Many in vitro models
are able to induce a non-replicative M.tb state but fail to
demonstrate or measure other characteristics. Thus, it is currently
unclear how the phenotype of sub-populations of bacilli from
different models overlap, and how important each stimulus is to the
generation of bacteria that may survive prolonged chemotherapy.
Murine models are most frequently used for determining the
sterilising activity of new compounds, however the translation of
these results to the human system is problematic since tubercu-
lous mice lack lesion types characteristic of human disease. Re-
engineering the host (and/or pathogen) may succeed in transform-
ing TB disease immunopathology to more closely resemble that of
human infection. An alternative approach sees the adoption of a
number of different models alongside the murine model that
reﬂect the progression of human lung pathology for the study of
drug efﬁcacy in lung lesions. Either way, the development of better
strategies for drug screening is hampered by the lack of adequate
knowledge about the biological features of both the tubercle bacilli
and host immunity during TB infection of the human lung. We
suggest the following priorities for future research into the
signiﬁcance of M.tb population heterogeneity in human disease
and novel drug development strategies:
1. We need better models that deﬁne the action of anti-TB drugs
against speciﬁc sub-populations of M.tb bacilli, characterised
using standardised parameters that may be used to compare
between systems.
2. We require methodologies for characterising complex popula-
tions of bacilli, in an alternative approach to (1.), to directly
mimic the heterogeneous M.tb population structure found
during human disease.
3. Deﬁnitions of bacterial states (for example: dormant, latent,
active growth, tolerant) would be useful to align thinking and
enable study comparison.
4. Further exploration is needed into the role of host processes in
generating sub-populations of phenotypically-distinct bacilli
and knowledge of whether these subsets of bacilli are conﬁned
to speciﬁc anatomical locations during disease.
5. Finally, an understanding of the clinical signiﬁcance of these
M.tb sub-populations in human disease is necessary; does
population size or location matter, and is there signiﬁcant
patient-to-patient variation?
This is a tall order, and successful anti-TB drug regimens have
been developed in the past with little knowledge of these
processes. However, a greater understanding of the action of
existing and novel antimicrobials on M.tb subpopulations that are
able to persist through drug therapy will drive a paradigm shift in
TB chemotherapy options, signiﬁcantly reducing treatment length
and eliminating relapse.
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